Copaxone Slows Progression Of Disability, Reduces Relapses In MS
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Copaxone Slows Progression Of Disability, Reduces Relapses In MS

TORONTO, ON -- March 18, 1998 – Research published in the current issue of Neurology shows that Copaxone(R) (glatiramer acetate for injection) can actually slow the progression of relapse-remitting Multiple Sclerosis (MS).

The researchers found that Copaxone reduces the number of relapses and slows the progression of disability in patients with relapsing-remitting multiple sclerosis. A clinical trial that ran for nearly three years has shown that the longer patients take Copaxone(R), the better the results compared to placebo.

The research, conducted at 11 medical centres in the United States, has significant implications for Canadians with multiple sclerosis.

Multiple sclerosis is a chronic, often progressive disease of the central nervous system (brain, spinal cord and optic nerves), which affects 300,000 people in the United States (Approximately 10,000 people are diagnosed each year). The disease most often appears in people between the ages of 20 and 40 -- approximately 73 percent of people with multiple sclerosis are female.

More information on: Copaxone.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities